These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 35543733)

  • 1. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
    Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
    Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic lymph-node staging with
    Jansen BHE; Bodar YJL; Zwezerijnen GJC; Meijer D; van der Voorn JP; Nieuwenhuijzen JA; Wondergem M; Roeleveld TA; Boellaard R; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):509-520. PubMed ID: 32789599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic accuracy of
    Rajwa P; Heidenreich J; Drzezga A; Schmidt M; Shariat SF; Heidenreich A
    Prostate; 2024 Jan; 84(1):74-78. PubMed ID: 37750292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy.
    Spena G; Moretti TB; Dávila FS; Dos Anjos G; Khan I; Calace FP; Aveta A; Pandolfo SD; Tufano A; Izzo A; Farias A; Perdonà S; Maes K
    Minerva Urol Nephrol; 2024 Aug; 76(4):467-473. PubMed ID: 39051893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
    BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
    Haxhimolla J; Kua B; Gilbourd D; Haxhimolla H
    Semin Oncol Nurs; 2020 Aug; 36(4):151044. PubMed ID: 32723519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
    Hope TA; Eiber M; Armstrong WR; Juarez R; Murthy V; Lawhn-Heath C; Behr SC; Zhang L; Barbato F; Ceci F; Farolfi A; Schwarzenböck SM; Unterrainer M; Zacho HD; Nguyen HG; Cooperberg MR; Carroll PR; Reiter RE; Holden S; Herrmann K; Zhu S; Fendler WP; Czernin J; Calais J
    JAMA Oncol; 2021 Nov; 7(11):1635-1642. PubMed ID: 34529005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Kopp D; Kopp J; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz PI; Salomon G; Wiggermann P; Hammerer P; Schiffmann J
    Urol Int; 2022; 106(1):56-62. PubMed ID: 33965965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
    Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
    Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kopp J; Kopp D; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz P; Schoerner W; Hammerer P; Schiffmann J
    World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
    Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD
    J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.